Are Vibration Plates Worth the Hype? Here’s What Experts Say - Health.com

Skip to main contentNavigating the shift from volume to value in healthcareJoseph Villa emphasizes the importance of understanding AI's true capabilities in healthcareOct. 10, 20263 min read Pietje Kobus-McAllisterWinter is coming, Joseph Villa, founder and CEO of Bigbee Labs, Inc., predicts regarding the future of artificial intelligence (AI). Villa shared his thoughts at the second annual HealthAI summit, hosted by HealthInno on October 8 in Albuquerque, NM. The summit drew health leaders and medical professionals from New Mexico and beyond. The audience was invited to write their questions and concerns about AI on sticky notes and post them on a wall. Later in the day, notes with solutions and ideas would be added. As AI becomes increasingly prominent in healthcare, organizations must distinguish between what the technology can actually do and what vendors claim it can do, Villa said.

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.